M5717 and Pyronaridine tetraphosphate
Sponsors
Merck Healthcare KGaA
Conditions
Malaria
Phase 2
MS201618_0033
Active, not recruitingPACTR202302515279954
Start: 2023-02-20Target: 137Updated: 2026-01-27
MS201618_0034 - Phase 2a Proof-of-Concept, Multicenter, Randomized, Open Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of a Single Dose of the Combination M5717-pyronaridine as Chemoprevention in Asymptomatic Adults and Adolescents with Plasmodium falciparum Malaria Infection (CAPTURE-2).
RecruitingPACTR202312609154425
Start: 2023-09-10Target: 192Updated: 2026-01-27